Ann: 2012 Annual Report , page-19

No worries TaneNui

Muz also did some work, after your post on this thread, to look at who left the top 20 in the past year. (thanks Muzz)

From looking at the top 200, I saw that some had downsized and others had left, transocean were one that had gone without a trace, which when you look at mjc's post was a lot of shares to be redistributed.

I did a bit of work on this a little while ago to see where the shares were being taken up

Here is the post number that started that thread

7610431

These TOP 20 shares appear to be have been taken up by the 21-200.

I guess what you are really asking is why hang around Drinking the Kool-Aid

I can only speak personally for my reasons to stay

I work in the health sector, a lot closer to the care delivery end than this company, and I have stepped now more so into the performance KPI realm.

With the movement towards self governance in the public hospital and health networks I am starting to so a fresh set of eyes come in from the board level and really challenge the business of health delivery.

These institutions are having to think differently.

There is a search for efficiency within their organisations that they have not really been tasked so strongly to be looked at before, as they could always rely on budgets getting propped up each year.

I think that technologies such as POC that enable time and cost saving along with better outcomes will be eagerly taken up. Any technology that enables real time decisions to be made about treatment options and as such prevent or reduce admission times, I think, will be invested in by these "lean thinking" organisations.

With an aging population and rising demand, the cost of care will be examined on multiple fronts. If ADO's technology, through their royalty partnership agreements, can assist to speed up care and drive down cost I think that there is a ready market.

There is a move to 're-shape supply' or in other words prevent or minimise the illnesses that the finite supply of money can handle. I have heard recently leaders in the health sphere talking about the rising demand on Australia's GDP of health care to the point of a large chunk will need to be spent on hospitals, I laughed when one esteemed professor said "there will be no roads or schools or any other infrastructure, but it won't matter because we will all be in the hospital anyway!"

Ok this reshaping of supply thinking and how technology could help.

An example would be when an ambulance is called to attend to someone with Acute Coronary Syndrome.

The link to the slide show is interesting in that it talks about "the golden hour"

"The golden hour

Maximum damage to heart muscle

Maximum efficacy of treatment seen

Survival is best if thrombolysis is given within this time period

Each minute of delay in the first 3 hours confers 10 lost days of survival"

The idea is to prevent the Reperfusion injury (is the tissue damage caused when blood supply returns to the tissue after a period of ischemia or lack of oxygen).

The standard now would be to get them as quickly as possible to an already crowded A&E department so that further tests such as a more sensitive ECG could be taken and to check on cardiac markers (via a blood test) to see if the heart muscle has been damaged and the person needs treatment admission etc.

These cardiac markers in this case are a particular protein associated with only the heart muscle, and is released when it is dying. Tropinin is the name of the protein

Imagine if the determination of cardiac markers could happen with the first 5 minutes of the ambulance arriving at the patients home, with the authority to start treatment then and there??

As we know we are mostly fairly slow to seek treatment when experiencing chest pain Time to Treatment for Acute Coronary Syndromes: The Cost of Indecision

As such we would have a better chance of survival, "Time to treatment for symptoms of ACS can be a matter of life and death. Data suggest up to half of patients with ACS experience sudden death prior to arrival in the emergency department (ED)"

So better treatment, faster treatment, less disability, ? reduced length of stay, cheaper treatment = advantage.

OK here is the long "politburo" bow!

If hm's aunty is right and all the other guesses are right around Mix&Go being or becoming part of the solution for Phillips and bioMerieux Partner for PoC Handheld Diagnostic Solutions

Acute Coronary Syndrome – fast and accurate patient triage then there is the potential for a ready built demand in every ambulance, GP surgery and A&E department and a revenue stream, down the track for ADO.

Their stated aim is interesting at the bottom of the announcement article above where bioMerieux, around the quality of the Point of Care testing, state

" bioMerieux is already recognized among clinicians for its high medical value tests, which include the VIDAS range of cardiac emergency markers: Troponin I Ultra, Myoglobin, CK-MB, D-Dimer and NT-proBNP. The solutions co-developed with Philips will be complementary to VIDAS, giving clinicians the option of point-of-care testing without compromising on assay performance"

I see this as one example of cost reduction and improved care for the consumer of health services.......... you & me.

If testing can improve, just think of the savings in other areas of time and resources........ It's all about early intervention, prevention and promotion! It's too late or costly to wait............

I think it has taken a long time for ADO to guard their patents and give confidence to their partners to sign up. Now that is being tied down after 6 + years of waiting it may promote movement

You have a free carry position, rather than just the cash profit, so you probably think the same way, in that there is a future for this spec stock..............

Happy to wait and drink my Kool-aid.